scholarly journals Recent Progress on Lipid Intake and Chronic Kidney Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-11 ◽  
Author(s):  
Ke Pei ◽  
Ting Gui ◽  
Chao Li ◽  
Qian Zhang ◽  
Huichao Feng ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Recent Progress ◽  
Lipid Uptake ◽  
Vicious Cycle ◽  
Therapeutic Approaches ◽  
Lipid Abnormalities ◽  
Novel Therapeutic

The incidence of chronic kidney disease (CKD) is associated with major abnormalities in circulating lipoproteins and renal lipid metabolism. This article elaborates on the mechanisms of CKD and lipid uptake abnormalities. The viewpoint we supported is that lipid abnormalities directly cause CKD, resulting in forming a vicious cycle. On the theoretical and experiment fronts, this inference has been verified by elaborately elucidating the role of lipid intake and accumulation as well as their influences on CKD. Taken together, these findings suggest that further understanding of lipid metabolism in CKD may lead to novel therapeutic approaches.

Lipid Metabolism in Chronic Kidney Disease: The Role of Statins in Cardiovascular Risk

2007 ◽  
Vol 17 (1) ◽  
pp. 75-78 ◽  
Author(s):  
Christoph Wanner ◽  
Christiane Drechsler ◽  
Vera Krane
Keyword(s):  
Chronic Kidney Disease ◽  
Cardiovascular Risk ◽  
Lipid Metabolism ◽  
Kidney Disease

scholarly journals Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases

2021 ◽  
Vol 11 (8) ◽  
pp. 820
Author(s):  
Mengyuan Ge ◽  
Sandra Merscher ◽  
Alessia Fornoni
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Recent Progress ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Glomerular Diseases ◽  
Intracellular Lipids ◽  
Lipid Modifying Agents ◽  
Made In

Although dyslipidemia is associated with chronic kidney disease (CKD), it is more common in nephrotic syndrome (NS), and guidelines for the management of hyperlipidemia in NS are largely opinion-based. In addition to the role of circulating lipids, an increasing number of studies suggest that intrarenal lipids contribute to the progression of glomerular diseases, indicating that proteinuric kidney diseases may be a form of “fatty kidney disease” and that reducing intracellular lipids could represent a new therapeutic approach to slow the progression of CKD. In this review, we summarize recent progress made in the utilization of lipid-modifying agents to lower renal parenchymal lipid accumulation and to prevent or reduce kidney injury. The agents mentioned in this review are categorized according to their specific targets, but they may also regulate other lipid-relevant pathways.

scholarly journals Obesity-Related Chronic Kidney Disease—The Role of Lipid Metabolism

Metabolites ◽  
2015 ◽  
Vol 5 (4) ◽  
pp. 720-732 ◽  
Author(s):  
Peter Mount ◽  
Matthew Davies ◽  
Suet-Wan Choy ◽  
Natasha Cook ◽  
David Power
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease

scholarly journals Novel therapeutic approaches for chronic kidney disease due to glomerular disorders

2016 ◽  
Vol 311 (1) ◽  
pp. F63-F65 ◽  
Author(s):  
Maria Del Nogal-Avila ◽  
Hector Donoro-Blazquez ◽  
Manish K. Saha ◽  
Caroline B. Marshall ◽  
Lionel C. Clement ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Clinical Trials ◽  
Kidney Disease ◽  
Therapeutic Strategies ◽  
Therapeutic Approaches ◽  
The Past ◽  
Disease Mechanisms ◽  
Toxic Drugs ◽  
Novel Therapeutic

Improved understanding of glomerular disease mechanisms over the past decade has led to the emergence of new and targeted therapeutic strategies for chronic kidney disease (CKD). Most promising among these are the administration of recombinant mutated human angiopoietin-like 4, sialic acid-related sugars that induce sialylation in vivo, compounds related to Bis-T-23, and immune depletion of the soluble urokinase receptor from the circulation. Taking these therapeutic strategies into clinical trials will be the first step away from repurposed and relatively toxic drugs currently used for treating kidney disease.

scholarly journals Lipid metabolism and levels of proinflammatory cytokines in patients with type 2 diabetes with diabetic nephropathy depending on the stage of chronic kidney disease

2012 ◽  
Vol 9 (2) ◽  
pp. 53-56
Author(s):  
Y V Khasanova ◽  
A B Galkina ◽  
A A Nelaeva ◽  
I V Medvedeva
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Diabetic Nephropathy ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Proinflammatory Cytokines ◽  
Diabetes Development ◽  
Lipid Abnormalities ◽  
Relationship Of

Aim: to study the role and relationship of lipid metabolism and levels of proinflammatory cytokines in patients with type 2 diabetes mellitus (DM2) with diabetic nephropathy (DN), depending on the stage of chronic kidney disease (CKD). Materials and Methods: a total of 240 patients with type 2 diabetes in the early stages of DN and CKD were studied. Results: in patients with type 2 diabetes development of DN was associated with an increased level of proinflammatory cytokines and lipid abnormalities (hypertriglyceridemia). We found a negative correlation between the level of triglycerides (TG) and glomerular filtration rate (GFR) (r = -0,43) and a direct correlation between the level of IL-6 and TG (r = 0,48). Conclusions: increased levels of proinflammatory cytokines and triglycerides increase the risk of development and progression of DN and CKD.

Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Antoney J. Ferrey ◽  
Ramy Hanna ◽  
Uttam G. Reddy ◽  
Ekamol Tantisattamo ◽  
Kamyar Kalantar-Zadeh ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Therapeutic Approaches ◽  
Novel Therapeutic

scholarly journals The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease

2013 ◽  
Vol 305 (6) ◽  
pp. R559-R565 ◽  
Author(s):  
Jennifer M. Sasser
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Reproductive System ◽  
Experimental Models ◽  
Target Organ ◽  
Potential Therapeutic Role ◽  
Fibrotic Diseases ◽  
Structural Impacts ◽  
Novel Therapeutic

Emerging evidence supports a potential therapeutic role of relaxin in fibrotic diseases, including chronic kidney disease. Relaxin is a pleiotropic hormone, best characterized for its role in the reproductive system; however, recent studies have demonstrated a role of relaxin in the cardiorenal system. Both relaxin and its receptor, RXFP1, are expressed in the kidney, and relaxin has been shown to play a role in renal vasodilation, in sodium excretion, and as an antifibrotic agent. Together, these findings suggest that the kidney is a target organ of relaxin. Therefore, the purpose of this review is to describe the functional and structural impacts of relaxin treatment on the kidney and to discuss evidence that relaxin prevents disease progression in several experimental models of kidney disease. In addition, this review will present potential mechanisms that are involved in the therapeutic actions of relaxin.

Sign in / Sign up

Export Citation Format

Share Document